Skip to main content
. 2021 May;9(9):761. doi: 10.21037/atm-19-4511

Figure 2.

Figure 2

Representative CYR61 IHC of BC. (A) Low CYR61 expression is shown in NMIBCs (top left 100×, top right 200×, Ta stage); high CYR61 protein expression in MIBCs (lower left 100×, lower right 200×, T2 stage). (B) Kaplan-Meier survival analysis of CYR61 expression in 108 BC patients (log-rank test). Relationship of CYR61 expression and patients’ OS: low expression, n=66; high expression, n=42 (P=0.041, log-rank =4.191). (C) Disease-free survival curves from the time of BC diagnosis by CYR61 expression. Low expression, n=66; high expression, n=42 (P=0.571, log-rank =0.312). CYR61, cysteine-rich angiogenic inducer 61; IHC, immunohistochemistry; BC, bladder cancer; NMIBC, non-muscle-invasive BC; MIBC, muscle-invasive BC; OS, overall survival.